| Literature DB >> 35233326 |
Yukihiro Otaka1,2, Daiki Uchida1, Kinue Shimizu-Arii3, Nobuyoshi Ishiyama1, Keiko Kawai-Kowase2.
Abstract
Antineutrophil cytoplasmic antibody (ANCA)-associated renal-limited vasculitis (RLV) is a minor subtype of small vessel vasculitis characterized by the inflammation of blood vessels, tissue damage, and loss of renal function localized in the kidney without systemic involvements. Here, we report a case of myeloperoxidase (MPO) ANCA-associated RLV in a young adult woman in Japan presenting chronic hematuria and newly overt proteinuria. Percutaneous renal biopsy revealed focal fibro-cellular crescent glomerulonephritis and the absence of other small vasculitides, tubular atrophy, and interstitial fibrosis. Therapeutic intravenous methylprednisolone pulse followed by oral prednisolone was administered as a remission induction. The patient's serum MPO-ANCA level gradually decreased, coinciding with dramatic changes in proteinuria and hematuria after therapeutic glucocorticoid administration. Renal function was maintained within the normal range, and disease activity was well-tolerated throughout the follow-up period for more than 14 weeks. While the incidence of RLV is rare among younger patients, it occurs with asymptomatic hematuria and proteinuria, which is important in differentiating RLV from typical glomerulonephritis. The overall prognosis of ANCA-associated RLV potentially depends on the severity of extrarenal involvements. Early diagnosis, appropriate treatment, and regular maintenance are essential for controlling and treating RLV. Due to the nontypical case presented here, further investigation is recommended to improve the diagnosis strategies and treatment options for this disease.Entities:
Keywords: antineutrophil cytoplasmic antibody; fibro-cellular crescent glomerulonephritis; focal category; microscopic polyangiitis; myeloperoxidase; renal-limited vasculitis
Year: 2022 PMID: 35233326 PMCID: PMC8881747 DOI: 10.7759/cureus.21654
Source DB: PubMed Journal: Cureus ISSN: 2168-8184
Laboratory findings on admission
Abbreviations: ANCA, anti-neutrophil cytoplasmic antibody; CH50, 50% hemolytic complement activity; dsDNA, double-stranded deoxyribonucleic acid; eGFR, estimated glomerular filtration rate calculated by the Japanese equation for Modification of Diet in Renal Disease [6]); FEIA, fluorescence enzyme immunoassay; GBM, glomerular basement membrane; Ig, immunoglobulin; LA, latex agglutination turbidimetric immunoassay; MPO, myeloperoxidase; PR3, proteinase 3; RBC, red blood cell; WBC, white blood cell
| Items | Values | |
| WBC count | 11,170 | /μL |
| RBC count | 4.64 × 106 | /μL |
| Reticulocyte | 143,376 | /μL |
| Hemoglobin | 12.3 | g/dL |
| Hematocrit | 39.2 | % |
| Platelet count | 534,000 | /μL |
| Total protein | 7.2 | g/dL |
| Albumin | 4.4 | g/dL |
| Lactate dehydrogenase | 146 | IU/L |
| Urea nitrogen | 10.9 | mg/dL |
| Creatinine | 0.57 | mg/dL |
| eGFR creatinine | 108 | mL/min/1.73m2 |
| C-reactive protein | <0.05 | mg/dL |
| Ferritin | 106.3 | ng/mL |
| Rheumatoid factor (LA) | 3 | IU/mL |
| IgA | 127 | mg/dL |
| IgE | 113 | IU/mL |
| IgG | 1,325 | mg/dL |
| IgM | 133 | mg/dL |
| CH50 | 57 | U/mL |
| Complement component 3 | 99 | mg/dL |
| Complement component 4 | 15.0 | mg/dL |
| Anti-nuclear antibody | Less than 1:40 | |
| MPO-ANCA (FEIA) | 681.0 | IU/mL |
| PR3-ANCA (FEIA) | <0.5 | IU/mL |
| Anti-GBM antibody (FEIA) | 0.6 | U/mL |
| Cryoglobulin | Negative | |
| Anti-dsDNA antibody (FEIA) | 1.1 | IU/mL |
| Hepatitis-B surface antigen | Negative | |
| Hepatitis-C virus antibody | Negative | |
Figure 1Histopathology of renal biopsy specimens
(a) Focal fibro-cellular crescent formation (periodic acid–Schiff stain); (b) Unremarkable tubular atrophy and interstitial fibrosis (Masson’s trichrome stain); (c) Focal widening of the subendothelial spaces in the glomerulocapillary (arrows), lamination, and uneven thickening and thinning of basement membrane (electron microscopy)
Figure 2The changes in proteinuria, microscopic hematuria, and serum myeloperoxidase-antineutrophil cytoplasmic antibody (MPO-ANCA) throughout treatments